Clinical Trial Details

NCT ID: NCT01621321
Date Last Changed: December 26, 2014


Research Study Summary

A Phase 2/Phase 3 clinical study for patients with Allergic Bronchopulmonary Aspergillosis

Research Study Title

A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis


This is a research project to evaluate the efficacy and safety of two different treatment protocols in Allergic bronchopulmonary Aspergillosis.

To Learn more

Recruitment Details

Both Male and Female
15 to 65 Years
Overall Status
Lead Sponsor
Postgraduate Institute of Medical Education and Research
36 Months
Facility Type


Both Male and Female ages 15 Years to 65 Years

Inclusion Criteria:

Presence of all the following three criteria:

  • Immediate cutaneous hyperreactivity on aspergillus skin test

  • Elevated total IgE levels > 1000 IU/mL

  • A fumigatus specific IgE levels > 0.35 kUA/L

And, two of the following criteria:

  • Presence of serum precipitating antibodies against A fumigatus

  • Fixed or transient radiographic pulmonary opacities

  • Total eosinophil count > 1000/µL

  • Central bronchiectasis on HRCT

Exclusion Criteria:

  • Failure to give informed consent

  • Intake of glucocorticoids for more than three weeks in the preceding six months

  • Enrollment in another trial of ABPA

  • Any exposure to azoles in the last six months

Site Locations (1)

Country State City Zip Facility and Contact
India Chandigarh 160012 Postgraduate Institute of Medical Education and Research

Ritesh Agarwal, MD, DM
Principal Investigator


Ritesh Agarwal, MD, DM

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.